ANTHONY SANTOS: Open Payments
NPI 1750610168 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,633 in 94 payments from 10 companies in 2025. Trend: 2023 $1,727 · 2024 $1,592 · 2025 $6,633
Speaker / faculty: $2,880Food & beverage: $2,047Travel & lodging: $946Consulting: $760
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 22 | $4,538 |
| Intercept Pharmaceuticals, Inc. | 1 | $760 |
| Madrigal Pharmaceuticals | 22 | $459 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $330 |
| ABBVIE INC. | 12 | $174 |
| Ipsen Biopharmaceuticals, Inc | 7 | $145 |
| Novo Nordisk Inc | 6 | $117 |
| ORPHALAN INC | 2 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $30 |
| Fujifilm Healthcare Americas Corporation | 1 | $23 |
Products named: Livdelzi, OCALIVA, REZDIFFRA, XIFAXAN, IQIRVO, Wegovy, MAVYRET, CREON.
Industry payments across TX — which companies pay providers there.
